Published in Neurology on June 01, 1995
Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol (2007) 2.17
Intellectual function in Mexican children living in a mining area and environmentally exposed to manganese. Environ Health Perspect (2010) 1.80
Manganese and Parkinson's disease: a critical review and new findings. Environ Health Perspect (2010) 1.66
Industrial toxicants and Parkinson's disease. Neurotoxicology (2012) 1.65
Manganese and its role in Parkinson's disease: from transport to neuropathology. Neuromolecular Med (2009) 1.54
Brain magnetic resonance imaging and manganese concentrations in red blood cells of smelting workers: search for biomarkers of manganese exposure. Neurotoxicology (2006) 1.52
Brain deposition and neurotoxicity of manganese in adult mice exposed via the drinking water. Arch Toxicol (2013) 1.44
Effects of chronic manganese exposure on cognitive and motor functioning in non-human primates. Brain Res (2006) 1.27
Dystonia and chorea in acquired systemic disorders. J Neurol Neurosurg Psychiatry (1998) 1.18
Biomarkers of manganese intoxication. Neurotoxicology (2010) 1.09
Cerebrospinal fluid to brain transport of manganese in a non-human primate revealed by MRI. Brain Res (2008) 1.07
Manganese exposure is cytotoxic and alters dopaminergic and GABAergic neurons within the basal ganglia. J Neurochem (2009) 1.06
Acquired hepatocerebral degeneration. J Neurol (2009) 0.98
Methylcyclopentadienyl manganese tricarbonyl: health risk uncertainties and research directions. Environ Health Perspect (1998) 0.83
Incorporating genetics and genomics in risk assessment for inhaled manganese: from data to policy. Neurotoxicology (2009) 0.82
Chronic exposure to manganese alters brain responses to amphetamine: a pharmacological magnetic resonance imaging study. Toxicol Sci (2010) 0.80
Identification of dopaminergic neurons of the substantia nigra pars compacta as a target of manganese accumulation. Metallomics (2015) 0.77
High signal intensity on T1 weighted MRI of the anterolateral column of the spinal cord in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (1997) 0.77
Multiple receptors for dopamine. Nature (1979) 5.51
Double-blind study of botulinum toxin in spasmodic torticollis. Lancet (1986) 4.54
Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med (1974) 4.10
Levodopa failure in chronic manganism. Neurology (1994) 3.80
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med (1995) 3.64
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology (2003) 3.62
Manganism and idiopathic parkinsonism: similarities and differences. Neurology (1994) 3.34
Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA (1999) 3.22
Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol (1998) 3.20
Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science (2001) 3.18
A neuronal morphologic type unique to humans and great apes. Proc Natl Acad Sci U S A (1999) 2.81
Criteria for diagnosing Parkinson's disease. Ann Neurol (1992) 2.78
L-dopa in postencephalitic parkinsonism. Lancet (1969) 2.72
A scoring error in the Mini-Mental State test. Can J Psychiatry (1993) 2.69
Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat Genet (1995) 2.66
Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology (1983) 2.47
Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science (1980) 2.45
Bromocriptine in Parkinsonism. Br Med J (1974) 2.44
Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings. Lancet (2003) 2.38
Aetiology of Parkinson's disease. Lancet (1984) 2.32
Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol (2001) 2.31
Design of an efficient position sensitive gamma ray detector for nuclear medicine. Phys Med Biol (1986) 2.20
Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol (1990) 2.18
Bacterial colonization of the vagina during pregnancy in four ethnic groups. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol (1996) 2.10
The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol (2000) 2.08
The pathology of Legionnaires' disease. Fourteen fatal cases from the 1977 outbreak in Vermont. Arch Pathol Lab Med (1978) 2.06
Rising mortality from motoneuron disease in the USA, 1962-84. Lancet (1989) 2.05
Vocal cord paralysis in the Shy-Drager syndrome. J Neurol Neurosurg Psychiatry (1979) 2.04
Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol (1999) 2.02
Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology (1999) 1.97
Reaction time in Parkinson's disease. Brain (1981) 1.92
Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology (2006) 1.89
Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology (2004) 1.87
Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol (1996) 1.87
X-linked scapuloperoneal syndrome. J Neurol Neurosurg Psychiatry (1972) 1.87
Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology (2004) 1.86
L-dopa in idiopathic parkinsonism. Lancet (1969) 1.86
A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet (1998) 1.84
Hypotension caused by L-dopa. Br Med J (1970) 1.81
Positron emission tomography in manganese intoxication. Ann Neurol (1989) 1.78
Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia (2006) 1.72
Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol (1995) 1.69
Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology (2006) 1.68
The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol (1992) 1.67
Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment? Lancet (1986) 1.65
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol (2000) 1.65
Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science (1982) 1.63
Cardiovascular reflexes in Parkinsonism. Clin Sci (1971) 1.62
Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry (1999) 1.62
Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J (1971) 1.60
Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology (1996) 1.60
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Selegiline in Parkinson's disease. BMJ (1995) 1.58
Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol (1990) 1.56
Investigation of a fatality from nonoccupational aluminum phosphide exposure: measurement of aluminum in tissue and body fluids as a marker of exposure. J Lab Clin Med (1993) 1.53
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry (1996) 1.52
Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology (1986) 1.50
Neurological manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease): report of 2 cases and review of the literature. Ann Neurol (1978) 1.50
Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry (2000) 1.49
Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol (1988) 1.49
Motor nerve conduction velocity in peroneal muscular atrophy: evidence for genetic heterogeneity. J Neurol Neurosurg Psychiatry (1974) 1.47
Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol (1991) 1.46
Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol (1998) 1.45
Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol (1997) 1.45
The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates. J Nucl Med (1991) 1.42
Action of dopamine on the human iris. Br Med J (1969) 1.42
Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem (1995) 1.41
Progressive dementia and gait disorder in a 78 year old woman. J Neurol Neurosurg Psychiatry (2000) 1.39
Hereditary form of parkinsonism--dementia. Ann Neurol (1998) 1.39
Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry (1998) 1.39
Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer's disease cases. Acta Neuropathol (1992) 1.38
Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med (1994) 1.35
Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci (1987) 1.33
Essential tremor. Clin Neuropharmacol (1983) 1.33
Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol (1992) 1.33
Olfactory impairment in Parkinson's disease. Neurology (1983) 1.30
Autosomal dominant dystonia-plus with cerebral calcifications. Neurology (2006) 1.27
Lesions of the putamen and dystonia: CT and magnetic resonance imaging. Neurology (1984) 1.26
Vibratory sense: a critical review. Brain (1966) 1.26
18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans. Can J Neurol Sci (1990) 1.26
A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci (1985) 1.26
Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol (1994) 1.26
Long-term treatment of parkinsonism with bromocriptine. Lancet (1978) 1.24
Nomifensine in parkinsonism. J Neurol Neurosurg Psychiatry (1976) 1.24
Postmortem studies in schizophrenia. Schizophr Bull (1998) 1.23
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol (1999) 1.22